MARLBOROUGH, Mass.--(BUSINESS WIRE)--May 15, 2018--Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the Company’s contact center, Sunovion Answers, has become a J.D. Power 2017 Certified Contact Center. Sunovion Answers has been recognized under the J.D. Power Certified Contact Center Program SM for providing “An Outstanding Customer Service Experience.”

Sunovion Answers is designed to provide personalized assistance for patients and their caregivers and health care providers. Specialists provide live phone support and offer medication information, insurance information and savings information to callers. They also help patients find support groups and other resources for further assistance.

According to J.D. Power’s Customer Service Practice, Sunovion Answers earned the certification for its dedication to providing the highest levels of customer satisfaction.

“Sunovion is proud to earn a J.D. Power Certified Contact Center award for Sunovion Answers,” said Nobuhiko Tamura, Chairman and Chief Executive Officer, Sunovion. “This distinction reinforces our commitment to providing an outstanding experience through our support services, keeping the patient at the center of everything we do.”

J.D. Power 2017 Certified Contact Center Program SM recognition is based on successful completion of a rigorous assessment process including an audit and exceeding a customer satisfaction benchmark through a survey of recent servicing interactions. For more information, visit www.jdpower.com/ccc.

About Sunovion Pharmaceuticals Inc. (Sunovion)

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.

Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the company’s websites:  www.sunovion.com, www.sunovion.eu  and  www.sunovion.ca. Connect with Sunovion on  TwitterLinkedInFacebook  and  YouTube.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. © 2018 Sunovion Pharmaceuticals Inc. All rights reserved.

For a copy of this release, visit Sunovion’s web site at www.sunovion.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20180515005428/en/

CONTACT: Sunovion Pharmaceuticals Inc.

Jennifer Baird, 508-787-4109

Senior Director, Corporate Communications

jennifer.baird@sunovion.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Sunovion Pharmaceuticals Inc.

Copyright Business Wire 2018.

PUB: 05/15/2018 08:00 AM/DISC: 05/15/2018 08:01 AM

http://www.businesswire.com/news/home/20180515005428/en